Kymera Therapeutics amends bylaws to designate federal courts for securities claims

Kymera Therapeutics, Inc.

Board approved amendment to Second Amended and Restated Bylaws on March 25, 2026.
Federal district courts designated exclusive forum for claims under Securities Act of 1933 and Exchange Act of 1934.
Amendment effective immediately; company may consent to alternative forum in writing.
Change made in response to recent amendments to Delaware General Corporation Law.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Kymera Therapeutics, Inc.: Amended bylaws to designate federal district courts as exclusive forum for Securities Act and Exchange Act claims (effective 2026-03-25).

Change: bylaw amendment
Effective: 2026-03-25

Exact text from the filing

On March 25, 2026, the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”), effective immediately, to designate the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Kymera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-129170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.